• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Regulatory

FDA approves Zavzpret zavegepant nasal spray for the treatment of migraine

The FDA has approved Pfizer's Zavzpret zavegepant (BHV-3500) calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the treatment of migraine. Pfizer said that it expects to launch Zavzpret in July 2023. The FDA accepted the NDA for the zavegepant (formerly "vazegepant") nasal spray submitted by Biohaven Pharmaceuticals in May 2022. Biohaven … [Read more...] about FDA approves Zavzpret zavegepant nasal spray for the treatment of migraine

FDA approves Amphastar’s naloxone nasal spray for the treatment of opioid overdose

The FDA has approved Amphastar Pharmaceuticals' NDA for 4 mg intranasal naloxone for the treatment of opioid overdose. According to the company, the nasal spray is delivered via a proprietary delivery device. A previous Amphastar NDA for a 2mg naloxone nasal spray received a CRL from the NDA in 2017, with the FDA asking for additional human factors and device … [Read more...] about FDA approves Amphastar’s naloxone nasal spray for the treatment of opioid overdose

FDA accepts Amneal’s ANDA for generic of Narcan naloxone nasal spray

According to Amneal Pharmaceuticals, the FDA has accepted the company's ANDA for a generic version of Narcan naloxone nasal spray, 4 mg, for the treatment of opioid overdose. Amneal generics Chief Commercial Officer Andy Boyer said, "Naloxone hydrochloride nasal spray is a critical tool in addressing the opioid public health emergency across the United States. We … [Read more...] about FDA accepts Amneal’s ANDA for generic of Narcan naloxone nasal spray

Firebrick Pharma files Pediatric Investigation Plan for Nasodine povidone-iodine nasal spray

Firebrick Pharma announced that it has filed a Pediatric Investigation Plan (PIP) with the EMA's Pediatric committee for its Nasodine povidone-iodine nasal spray as the company plans to submit a marketing application for Nasodine by the end of 2023. In April 2022, Firebrick initiated a Phase 2 study of Nasodine for the treatment of COVID-19. A Phase 3 trial of … [Read more...] about Firebrick Pharma files Pediatric Investigation Plan for Nasodine povidone-iodine nasal spray

Optinose submits sNDA for Xhance fluticasone propionate nasal spray to treat chronic sinusitus

Optinose announced that it has submitted an sNDA for a label expansion of Xhance fluticasone propionate nasal spray (OPN-375) for the treatment of chronic sinusitis without nasal polyps. Xhance has been approved for the treatment of nasal polyps in the US since 2017. In June 2022, the company announced that the second of two Phase 3 trials of Xhance for the treatment … [Read more...] about Optinose submits sNDA for Xhance fluticasone propionate nasal spray to treat chronic sinusitus

Beckley Psytech gets go-ahead for Phase 2b study of BPL-003 intranasal synthetic 5-MeO-DMT

Beckley Psytech said that the FDA has approved the company's IND for a Phase 2b study comparing 2 doses of BPL–003 intranasal dry powder synthetic 5-MeO-DMT (mebufotenin) in patients with treatment-resistant depression. According to Beckley Psytech, the proposed Phase 2b study, which is expected to be initiated in the first half of this year, is the first ever … [Read more...] about Beckley Psytech gets go-ahead for Phase 2b study of BPL-003 intranasal synthetic 5-MeO-DMT

FDA advisory committee recommends approval of Narcan naloxone nasal spray for OTC sales

The FDA's Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee have voted unanimously in favor of over-the-counter use of Narcan naloxone nasal spray for the reversal of opioid overdose.  In December 2022, the FDA accepted Emergent BioSolutions' sNDA for OTC sales of Narcan for priority review, with a PDUFA goal … [Read more...] about FDA advisory committee recommends approval of Narcan naloxone nasal spray for OTC sales

Orexo submits NDA for OX124 intranasal naloxone

Orexo announced that it has submitted an NDA for its OX124 intranasal naloxone for the reversal of opioid overdose. The company notes that FDA review is likely to take a little more than a year and says that it is planning for a launch in the first half of 2024. OX124 is based on the company's amorphOX particle engineering technology, which also underlies its … [Read more...] about Orexo submits NDA for OX124 intranasal naloxone

FDA accepts Opiant’s NDA for OPNT003 intranasal nalmefene

According to Opiant Pharmaceuticals, the FDA has accepted the company's NDA for OPNT003 intranasal nalmefene for the treatment of opioid overdose for priority review and has set a PDUFA date of May 22, 2023. In October 2022, Opiant announced that it had completed its rolling submission of the NDA for OPNT003. The company has received funding from the … [Read more...] about FDA accepts Opiant’s NDA for OPNT003 intranasal nalmefene

Vero Biotech closes $30 million financing to support commercialization of Genosyl tankless iNO system

Vero Biotech announced an investment of $30 million from Petrichor Healthcare Capital Management that will be used for commercialization of Vero's Genosyl DS tankless inhaled nitric oxide system. The company recently announced that it had received FDA approval for the third generation Genosyl DS for delivery of iNO to increase oxygenation in newborn infants with … [Read more...] about Vero Biotech closes $30 million financing to support commercialization of Genosyl tankless iNO system

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Interim pages omitted …
  • Page 98
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews